医药代表备案制来了!一旦“越界”将被列入“黑名单”

2019-01-03 佚名 中国制药网

1月2日,广东省卫健委等9部门联合下发《关于印发广东省2018年纠正医药购销领域和医疗服务中不正之风专项治理工作要点的通知》(以下简称《通知》)。《通知》显示了广东省2018年纠正医药购销领域和医疗服务中不正之风专项治理工作要点,包括规范药品耗材产销用行为,健全供应保障体系;加强医疗服务监管,规范医务人员行为;推进医药代表备案管理,构建回扣治理体系三个重点工作。其中,在推进医药代表备案管理工作方面

1月2日,广东省卫健委等9部门联合下发《关于印发广东省2018年纠正医药购销领域和医疗服务中不正之风专项治理工作要点的通知》(以下简称《通知》)。

《通知》显示了广东省2018年纠正医药购销领域和医疗服务中不正之风专项治理工作要点,包括规范药品耗材产销用行为,健全供应保障体系;加强医疗服务监管,规范医务人员行为;推进医药代表备案管理,构建回扣治理体系三个重点工作。

其中,在推进医药代表备案管理工作方面,明确要完善医药代表管理制度,规范院内工作行为。

具体来看,要求推进实施《医药代表备案管理办法(试行)》,规范医药代表从业行为,改善医疗服务环境,药品生产企业(上市许可持有人)应当公开其医药代表的备案信息。对医药代表加强相关的法律法规、职业道德、专业知识等方面的培训。

另外,督促医疗机构建立完善符合要求的医药代表院内接待流程,确保医药代表的院内行为有记录、可监控、能公开,改善医疗服务环境。加强医疗机构内部巡查监控制度,对于未按照院内要求开展工作的医药代表要坚决劝离。

同时,对于利用医药代表身份参与产品销售、药品统方、处理票款、商业贿赂、提供捐赠、误导用药、歪曲疗效、隐匿不良信息等与其工作无关的行为,应当列入“黑名单”并上报相关管理部门。对所属医药代表违规情况严重的医药企业实施多部门联合惩戒,形成一处失信、寸步难行的治理局面。

这也意味着,以后医药代表的工作将会透明化,过去灰色链行为不再能够继续维持,一旦“越界”将会被拉入“黑名单”,而且还会连同医药企业等多部门一起被严格整治,这对于规范医药代表行业和医药行业而言是重拳出击,有利于行业更规范、合理的发展,也有利于维护患者的利益。

实际上,广东省此次发布的文件是对国家版药代备案管理办法的响应和落实。

2018年8月23日,国家卫健委、国家医保局等九部委联合印发《2018年纠正医药购销领域和医疗服务中不正之风专项治理工作要点》,要求推进实施《医药代表备案管理办法(试行)》,规范医药代表从业行为,改善医疗服务环境,药品生产企业(上市许可持有人)应当公开其医药代表的备案信息。

业内表示,在该政策的推行下,有利于惩戒医药代表违规情况,规范医药生产、零售企业的行为,进一步改善医疗服务环境,对于患者的利益、社会的和谐稳定而言也是一大保障。

总的来看,广东省对医药代表备案管理制发布后,医药代表将处在涅盘重生的当口,能忍受改变的阵痛,就可能迎来新生,进入规范化、专业化的轨道。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-11-25 fengyqf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-11-20 drj2014
  4. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-01-05 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1666716, encodeId=59991666e163f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Nov 25 18:54:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755145, encodeId=952c1e5514592, content=<a href='/topic/show?id=2f82103280eb' target=_blank style='color:#2F92EE;'>#黑名单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103280, encryptionId=2f82103280eb, topicName=黑名单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52536838019, createdName=zhty5349, createdTime=Tue May 14 23:54:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718319, encodeId=bdf81e1831960, content=<a href='/topic/show?id=34cf424e727' target=_blank style='color:#2F92EE;'>#备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42477, encryptionId=34cf424e727, topicName=备案制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25e32549752, createdName=drj2014, createdTime=Wed Nov 20 09:54:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993960, encodeId=7c3b1993960af, content=<a href='/topic/show?id=1b42352e4ed' target=_blank style='color:#2F92EE;'>#医药代表备案制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35274, encryptionId=1b42352e4ed, topicName=医药代表备案制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Aug 15 08:54:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409769, encodeId=912d1409e69a2, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443600, encodeId=28801443600e8, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590956, encodeId=b85e159095678, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sat Jan 05 03:54:00 CST 2019, time=2019-01-05, status=1, ipAttribution=)]
    2019-01-05 cenghis

相关资讯

全国药代大检查,风暴来了!

全国反腐持续高压,在此形势下,如果医药行业这种不良风气还是刹不住,那只有用法律制裁,可能要抓人了!

2019年医药代表要大裁员?

这不单是一个优胜劣汰的时代,这更是一个无差别攻击的时代。想淘汰过剩产能,减少同类产品过多的情况,同时减少临床上辅助药过度使用情况,医疗行业在非常时期用了非常手段。 药物一致性评价、11城市带量采购、全国辅助用药目录每一项政策都如落地惊雷,影响着行业的走向,每一个政策可能都是一次市场格局洗牌的机会。外企,国企,大包,谁都无法独善其身,而作为这些公司一线的销售,公司的命运就是自己的职业命运。

上海部队医院严查医药代表!

近日多人反馈上海多家部队医院又开始严查医药代表,并且要求各科对诊室等进行清理,禁止科室内有代表名片、食品等,引起很多代表恐慌,MRCLUB网友反映称检查会翻抽屉,长征医院已有代表被带走。目前反馈过来的医院有海军军医大学附属长海医院、上海东方肝胆医院、上海长征医院。据大咪了解,事情起因是海军党委第3巡视组自8月上旬开始,开始对军医大学党委班子及其成员进行常规巡视。最近上海基本情况就是这样,同时也提醒

医药代表如何与不同学习风格的医生互动?

昨天是棍棍节,打开手机,或者走到街上,我们应该很明显的知道,我们正处于一个与十年前,甚至五年前完全不同的世界。

最后一个月了 医药代表应该控货吗?

还有两周时间,2018年即将过去,抛开那些顺其自然就能完成指标的家伙,对于很多医药代表来说,都需要下一个重要的决定:压货还是控货?

4 +7后大淘汰?药代反击了

医药代表即将淘汰、消失?